MinorGabapentinoids (antiepileptics)×Systemic decongestant, sympathomimetic
Updated · Methodology
Mechanism
Pregabalin is hardly metabolised: the kidneys excrete it unchanged, it does not bind to plasma proteins and it does not inhibit the metabolism of other drugs, so pharmacokinetic interactions are unlikely (pregabalin SmPC, European Medicines Agency, EMA). The liver metabolises less than 1% of a pseudoephedrine dose, 55–96% of the dose is excreted unchanged in urine, and the rate of elimination depends on urine pH (Respidina SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents say nothing about either drug affecting the elimination of the other. The pseudoephedrine interaction lists include central nervous system stimulants, antihypertensives, tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs) but mention neither pregabalin nor its class (Respidina SmPC, AEMPS). The pregabalin SmPC advises caution with central nervous system depressants (pregabalin SmPC, EMA), and pseudoephedrine is not one of them: it is a sympathomimetic that stimulates the nervous system (Respidina SmPC, AEMPS).
Symptoms
The documents describe no symptoms linked to this combination. Pregabalin most often causes dizziness and somnolence, and it can cause blurred vision, peripheral oedema and weight gain (Lyrica label, US Food and Drug Administration, FDA). Pseudoephedrine can raise blood pressure and heart rate and cause nervousness, insomnia and tremor. Its serious reactions include ischaemic optic neuropathy with sudden loss of vision, posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome with sudden severe headache (Respidina SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of pregabalin and pseudoephedrine need no change. No document names the pair, and pharmacokinetic interactions with pregabalin are unlikely (pregabalin SmPC, European Medicines Agency, EMA). Pseudoephedrine is used for as short a time as possible and no longer than the symptoms last. For the prolonged-release form, the maximum daily dose is 240 mg (Respidina SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use pseudoephedrine with caution in people with epilepsy or at risk of seizures (Respidina SmPC, AEMPS). Pseudoephedrine is contraindicated in severe renal failure and may need a dose adjustment in milder renal impairment (Respidina SmPC, AEMPS). Adjust the pregabalin dose to creatinine clearance (pregabalin SmPC, EMA). Stop pseudoephedrine in case of high blood pressure, fast or irregular heartbeat, nausea, headache or worsening headache, sudden loss of vision, or sudden severe headache, vomiting, confusion, seizures or visual disturbances (Respidina SmPC, AEMPS). If visual disturbance from pregabalin persists, consider further assessment (Lyrica label, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Lyrica (pregabalin) prescribing information (2025)– FDA label, DailyMed setid 60185c88-ecfd-46f9-adb9-b97c6b00a553, sections 5.4, 6.2
- EMA: Ficha técnica: Pregabalina (EU/1/04/279), secciones 4.4 y 4.5 (2024)– EMA, ficha técnica de Lyrica en CIMA (nº registro 104279015), revisión del texto 05/2024, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Pseudoefedrina, Respidina 120 mg comprimidos de liberación prolongada (nº registro 82731), sección 4.3 (2024)– AEMPS, CIMA, nº registro 82731, revisión 04/2024, secciones 4.3 y 4.4
- AEMPS: Ficha técnica: Pseudoefedrina, Respidina 120 mg comprimidos de liberación prolongada (nº registro 82731), sección 4.5 (2024)– AEMPS, CIMA, nº registro 82731, revisión 04/2024, secciones 4.5 y 5.1